耐去势转移性前列腺癌的骨转移消退

Q4 Medicine Revista mexicana de urologia Pub Date : 2016-03-01 DOI:10.1016/j.uromx.2015.12.002

R. Cortez-Betancourt , M. Pelayo-Nieto , E. Linden-Castro , I.A. Ramírez-Galindo , E.D. Rubio-Arellano , R.C. Rodríguez-Alvarado , A. González-Serrano , J.G. Sierra-Sosa , D. Espinosa-Perezgrovas , J.A. Morales-Covarrubias

{"title":"耐去势转移性前列腺癌的骨转移消退","authors":"R. Cortez-Betancourt , M. Pelayo-Nieto , E. Linden-Castro , I.A. Ramírez-Galindo , E.D. Rubio-Arellano , R.C. Rodríguez-Alvarado , A. González-Serrano , J.G. Sierra-Sosa , D. Espinosa-Perezgrovas , J.A. Morales-Covarrubias","doi":"10.1016/j.uromx.2015.12.002","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>There have been significant modifications in metastatic castration-resistant prostate cancer management in the last decade, with great changes in the treatment paradigm, even though the disease will ultimately continue to progress despite the currently available treatments.</p></div><div><h3>Case report</h3><p>A 72-year-old man diagnosed with castration-resistant prostate cancer underwent a bone scintigram that identified metastatic bone lesions. He was treated with abiraterone, with clinical and biochemical response. Follow-up revealed regression of bone metastasis documented in the bone scintigram.</p></div><div><h3>Conclusions</h3><p>This clinical case shows the particularity of apparent bone lesion regression in the context of metastatic castration-resistant prostate cancer after treatment with abiraterone acetate that also showed sustained clinical and biochemical response.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2015.12.002","citationCount":"0","resultStr":"{\"title\":\"Regresión de metástasis óseas en cáncer de próstata metastásico resistente a castración\",\"authors\":\"R. Cortez-Betancourt , M. Pelayo-Nieto , E. Linden-Castro , I.A. Ramírez-Galindo , E.D. Rubio-Arellano , R.C. Rodríguez-Alvarado , A. González-Serrano , J.G. Sierra-Sosa , D. Espinosa-Perezgrovas , J.A. Morales-Covarrubias\",\"doi\":\"10.1016/j.uromx.2015.12.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>There have been significant modifications in metastatic castration-resistant prostate cancer management in the last decade, with great changes in the treatment paradigm, even though the disease will ultimately continue to progress despite the currently available treatments.</p></div><div><h3>Case report</h3><p>A 72-year-old man diagnosed with castration-resistant prostate cancer underwent a bone scintigram that identified metastatic bone lesions. He was treated with abiraterone, with clinical and biochemical response. Follow-up revealed regression of bone metastasis documented in the bone scintigram.</p></div><div><h3>Conclusions</h3><p>This clinical case shows the particularity of apparent bone lesion regression in the context of metastatic castration-resistant prostate cancer after treatment with abiraterone acetate that also showed sustained clinical and biochemical response.</p></div>\",\"PeriodicalId\":34909,\"journal\":{\"name\":\"Revista mexicana de urologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.uromx.2015.12.002\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista mexicana de urologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2007408515001639\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408515001639","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

在过去十年中，转移性去势抵抗性前列腺癌的治疗发生了重大变化，治疗模式发生了巨大变化，尽管目前可用的治疗方法最终仍将继续发展。病例报告:一名72岁的男性被诊断患有去势抵抗性前列腺癌，接受了骨显像检查，确定了转移性骨病变。患者给予阿比特龙治疗，临床及生化反应良好。随访显示骨闪烁图显示骨转移灶消退。结论本病例显示了转移性去势抵抗性前列腺癌患者经醋酸阿比特龙治疗后骨损伤明显消退的特殊性，且临床和生化反应均持续。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Regresión de metástasis óseas en cáncer de próstata metastásico resistente a castración

Introduction

There have been significant modifications in metastatic castration-resistant prostate cancer management in the last decade, with great changes in the treatment paradigm, even though the disease will ultimately continue to progress despite the currently available treatments.

Case report

A 72-year-old man diagnosed with castration-resistant prostate cancer underwent a bone scintigram that identified metastatic bone lesions. He was treated with abiraterone, with clinical and biochemical response. Follow-up revealed regression of bone metastasis documented in the bone scintigram.

Conclusions

This clinical case shows the particularity of apparent bone lesion regression in the context of metastatic castration-resistant prostate cancer after treatment with abiraterone acetate that also showed sustained clinical and biochemical response.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Revista mexicana de urologia Medicine-Urology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.